New and Future Developments in Neurotoxins.

IF 2.5 3区医学 Q2 DERMATOLOGY

Dermatologic Surgery Pub Date : 2024-09-01 Epub Date: 2024-07-24 DOI:10.1097/DSS.0000000000004346

Steve Yoelin, Deirdre Hooper

{"title":"New and Future Developments in Neurotoxins.","authors":"Steve Yoelin, Deirdre Hooper","doi":"10.1097/DSS.0000000000004346","DOIUrl":null,"url":null,"abstract":"Background: There are 7 known serotypes of botulinum neurotoxins (A through G). Currently, commercially available toxins are those in serotypes A and B. This paper will discuss new toxins on the horizon, developments in prolonging and shortening the duration of outcomes, and novel therapeutic indications on the horizon.Objective: To provide insight into new toxins and new therapeutic modalities surrounding toxins on the horizon.Methods: The authors have reviewed the relevant literature and shared their insights and opinions as to future developments in toxin research and potential clinical applications.Conclusion: Botulinum neurotoxin type E's faster onset and shorter duration of effect represent true clinical differentiators. Future development of botulinum neurotoxin type E for aesthetic and therapeutic uses will be in areas where fast onset and short duration of effect are desirable. Current challenges with neuromodulators include the need for frequent treatments and lack of reversal agents. Agents to address both challenges and novel indications, including inhibition of melanogenesis, are being developed.","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/DSS.0000000000004346","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: There are 7 known serotypes of botulinum neurotoxins (A through G). Currently, commercially available toxins are those in serotypes A and B. This paper will discuss new toxins on the horizon, developments in prolonging and shortening the duration of outcomes, and novel therapeutic indications on the horizon.

Objective: To provide insight into new toxins and new therapeutic modalities surrounding toxins on the horizon.

Methods: The authors have reviewed the relevant literature and shared their insights and opinions as to future developments in toxin research and potential clinical applications.

Conclusion: Botulinum neurotoxin type E's faster onset and shorter duration of effect represent true clinical differentiators. Future development of botulinum neurotoxin type E for aesthetic and therapeutic uses will be in areas where fast onset and short duration of effect are desirable. Current challenges with neuromodulators include the need for frequent treatments and lack of reversal agents. Agents to address both challenges and novel indications, including inhibition of melanogenesis, are being developed.

查看原文本刊更多论文

神经毒素的新进展和未来发展。

背景：已知的肉毒杆菌神经毒素有 7 种血清型（A 至 G）。本文将讨论即将出现的新毒素、延长和缩短疗效持续时间方面的进展以及即将出现的新治疗适应症：深入探讨即将出现的新毒素和围绕毒素的新治疗方法：作者回顾了相关文献，并就毒素研究的未来发展和潜在的临床应用分享了他们的见解和观点：结论：E型肉毒杆菌神经毒素起效更快、持续时间更短，是真正的临床差异化优势。未来用于美容和治疗的 E 型肉毒杆菌神经毒素将在起效快、持续时间短的领域进行开发。神经调节剂目前面临的挑战包括需要频繁治疗和缺乏逆转剂。目前正在开发应对这两项挑战的药物和新的适应症，包括抑制黑色素生成。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatologic Surgery 医学-皮肤病学

CiteScore

3.10

自引率

16.70%

发文量

547

期刊介绍： Exclusively devoted to dermatologic surgery, the Dermatologic Surgery journal publishes the most clinically comprehensive and up-to-date information in its field. This unique monthly journal provides today’s most expansive and in-depth coverage of cosmetic and reconstructive skin surgery and skin cancer through peer-reviewed original articles, extensive illustrations, case reports, ongoing features, literature reviews and correspondence. The journal provides information on the latest scientific information for all types of dermatologic surgery including: -Ambulatory phlebectomy- Blepharoplasty- Body contouring- Chemical peels- Cryosurgery- Curettage and desiccation- Dermabrasion- Excision and closure- Flap Surgery- Grafting- Hair restoration surgery- Injectable neuromodulators- Laser surgery- Liposuction- Microdermabrasion- Microlipoinjection- Micropigmentation- Mohs micrographic surgery- Nail surgery- Phlebology- Sclerotherapy- Skin cancer surgery- Skin resurfacing- Soft-tissue fillers. Dermatologists, dermatologic surgeons, plastic surgeons, oculoplastic surgeons and facial plastic surgeons consider this a must-read publication for anyone in the field.